← Oncology Approval Tracker

FDA DECISION ·

Gazyva

obinutuzumab · Genentech

FDA approvalNew dosing regimenFollicular lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

An approximately 90-minute infusion option for patients with follicular lymphoma who had three standard-rate doses without an infusion reaction of grade 3 or higher.

LAMPGEN ANALYSIS

Why it matters

This schedule change can reduce chair time for patients who tolerated the first three administrations.

What research teams should watch

Check prior infusion-reaction grades before changing the rate and document the shortened schedule.

PRIMARY RECORDS

Sources